Le Lézard
Classified in: Health, Business
Subject: FINANCING AGREEMENTS

Langley BC Cannabis Ltd. Launches funding to raise $5 Million from Accredited Investors


LANGLEY, British Columbia, May 15, 2019 (GLOBE NEWSWIRE) -- Langley BC Cannabis Ltd. (the "Company") a prospective licensed cannabis cultivator under the Cannabis Act, is seeking to raise $5 Million in gross proceeds through the sale of 10,000,000 shares at $0.50 per share. This first round of financing is open to the Canadian market and will go to fund the facility purchase and construction retrofitting of their phase 1 facility, located in Langley British Columbia. Negotiations for the purchase of the Phase 1 facility are currently in their final phase.

Co-Founder and CEO of the company, Dion Tarbaj stated, "We are very pleased to be opening up this first round of financing to investors. With this funding in place, we will be able to begin construction on our phase 1 facility and move forward with our goal to receive a cultivation license from Health Canada."

This Phase 1 facility will be one of three initial planned expansions of Langley BC Cannabis LTD. facilities. With Phase 2 already in the planning stages, The Company aims to have both facilities licensed and operational by the end of 2021. Phase 1 is estimated to produce an estimated 4,500kg of dried cannabis in its first year with further expansion of that capacity in following fiscal years.

About the Company:

Langley BC Cannabis is an early stage cannabis cultivator applicant under Health Canada's Cannabis Act based in Langley BC, Canada. They have submitted their application to Health Canada and await the approval of Health Canada to begin cultivation of their first crop. The Company plans to produce high quality medical grade cannabis that will be affordable and accessible to all Canadians.

Media Contact:

Dion Tarbaj, Chief Executive Officer

Langley BC Cannabis Ltd.
2nd Floor, 8661 201 Street
Langley, BC, V2Y 0G9
Email:   [email protected]                           
Website: https://langleymj.com
Phone: +1-866-274-9286

 


These press releases may also interest you

at 03:20
Calliditas Therapeutics AB (STO: CALTX) ("Calliditas") today announces that its partner Viatris Pharmaceutical Japan G.K. ("Viatris") has initiated a phase III clinical trial in Japan with Nefecon, named VR-205 in the Japanese market, in Japanese...

at 03:00
Global biotechnology leader CSL Behring today announced that two hemophilia B patients were treated with the gene therapy HEMGENIX® (etranacogene dezaparvovec) at Hemophilia Treatment Centers in France. This milestone achievement makes HEMGENIX® the...

at 02:30
SOPHiA GENETICS , a cloud-native healthcare technology company and a global leader in data-driven medicine, today announced that Dhiti Omics Technologies, a precision molecular diagnostics service provider in India, is live on the SOPHiA...

at 01:15
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the Phase II/III SKYSCRAPER-06 study, evaluating tiragolumab plus Tecentriq® (atezolizumab) and chemotherapy versus pembrolizumab and chemotherapy as an initial...

at 01:05
BenevolentAI ("BenevolentAI" or the "Company") (Euronext Amsterdam: BAI), a leader in applying advanced AI to accelerate biopharma drug discovery, announces the appointment of Deutsche Numis as the Company's Financial and Capital Markets Adviser,...

3 jui 2024
YOUR LEGAL RIGHTS MAY BE AFFECTED There is a proposed settlement in a class-action lawsuit filed against Pfizer Inc., Pfizer Ireland Pharmaceuticals, Warner-Lambert Company, and Warner-Lambert Company LLC (collectively, "Pfizer") and Ranbaxy Inc.,...



News published on and distributed by: